Immunotherapy

• CASPIAN PROs Support Durvalumab Use For Extensive-Stage SCLC
• ATTRACTION-3 Confirms Nivolumab OS Benefit For Advanced Oesphageal Carcinoma
• Pembrolizumab Shows Early Triple-Negative Breast Cancer Potential
• Novice Research Dissemination Award #1: CART-19: a comparative between literature versus experience
• Liquid biopsies to predict response or resistance in IO
• Conclusions and perspectives
• ADP-A2M4 (MAGE-A4) in patients with Synovial Sarcoma
• MMR repair driven neoantigens
• Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
• Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
• Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow...
• Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
• Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
• Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
• Sex-based heterogeneity of efficacy of anticancer immunotherapy
• Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melan...
• Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
• Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
• Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafen...
• Clinical Significance of Immune-related Creatine Phosphokinase Increase Associated with Anti PD1/PD-L1 immunotherapies.
• Thyroid toxicity and anti-thyroid antibodies as predictive markers for patients treated with anti-PD1 checkpoint therapy
• Immune-related adverse events (irAEs) with single-agent PD-1 vs PD-L1 inhibitors: a meta-analysis of 8,730 patients from clinical trials
• Sarcoidosis-Like Reaction Mimics Progression in patients treated with immune checkpoint inhibitors
• Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
• Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)

• « Previous
• 1
• 2
• ...
• 90
• Next »